435 related articles for article (PubMed ID: 33478246)
1. Novel Insights Regarding Nitric Oxide and Cardiovascular Diseases.
Infante T; Costa D; Napoli C
Angiology; 2021 May; 72(5):411-425. PubMed ID: 33478246
[TBL] [Abstract][Full Text] [Related]
2. Inorganic nitrite and nitrate in cardiovascular therapy: A better alternative to organic nitrates as nitric oxide donors?
Münzel T; Daiber A
Vascul Pharmacol; 2018 Mar; 102():1-10. PubMed ID: 29174923
[TBL] [Abstract][Full Text] [Related]
3. Nitric oxide-independent stimulation of soluble guanylate cyclase with BAY 41-2272 in cardiovascular disease.
Boerrigter G; Burnett JC
Cardiovasc Drug Rev; 2007; 25(1):30-45. PubMed ID: 17445086
[TBL] [Abstract][Full Text] [Related]
4. Nitric oxide signalling in cardiovascular health and disease.
Farah C; Michel LYM; Balligand JL
Nat Rev Cardiol; 2018 May; 15(5):292-316. PubMed ID: 29388567
[TBL] [Abstract][Full Text] [Related]
5. Novel sGC Stimulators and sGC Activators for the Treatment of Heart Failure.
Breitenstein S; Roessig L; Sandner P; Lewis KS
Handb Exp Pharmacol; 2017; 243():225-247. PubMed ID: 27900610
[TBL] [Abstract][Full Text] [Related]
6. Soluble guanylate cyclase stimulator riociguat and phosphodiesterase 5 inhibitor sildenafil ameliorate pulmonary hypertension due to left heart disease in mice.
Pradhan K; Sydykov A; Tian X; Mamazhakypov A; Neupane B; Luitel H; Weissmann N; Seeger W; Grimminger F; Kretschmer A; Stasch JP; Ghofrani HA; Schermuly RT
Int J Cardiol; 2016 Aug; 216():85-91. PubMed ID: 27140341
[TBL] [Abstract][Full Text] [Related]
7. The Endothelium-Dependent Nitric Oxide-cGMP Pathway.
Mónica FZ; Bian K; Murad F
Adv Pharmacol; 2016; 77():1-27. PubMed ID: 27451093
[TBL] [Abstract][Full Text] [Related]
8. Role of redox signaling and poly (adenosine diphosphate-ribose) polymerase activation in vascular smooth muscle cell growth inhibition by nitric oxide and peroxynitrite.
Huang J; Lin SC; Nadershahi A; Watts SW; Sarkar R
J Vasc Surg; 2008 Mar; 47(3):599-607. PubMed ID: 18295111
[TBL] [Abstract][Full Text] [Related]
9. The importance of the nitric oxide-cGMP pathway in age-related cardiovascular disease: Focus on phosphodiesterase-1 and soluble guanylate cyclase.
Golshiri K; Ataei Ataabadi E; Portilla Fernandez EC; Jan Danser AH; Roks AJM
Basic Clin Pharmacol Toxicol; 2020 Aug; 127(2):67-80. PubMed ID: 31495057
[TBL] [Abstract][Full Text] [Related]
10. Exercise training induces eNOS coupling and restores relaxation in coronary arteries of heart failure rats.
Couto GK; Paula SM; Gomes-Santos IL; Negrão CE; Rossoni LV
Am J Physiol Heart Circ Physiol; 2018 Apr; 314(4):H878-H887. PubMed ID: 29351461
[TBL] [Abstract][Full Text] [Related]
11. Role of nitroxyl (HNO) in cardiovascular system: From biochemistry to pharmacology.
Sun HJ; Wu ZY; Cao L; Zhu MY; Nie XW; Huang DJ; Sun MT; Bian JS
Pharmacol Res; 2020 Sep; 159():104961. PubMed ID: 32474086
[TBL] [Abstract][Full Text] [Related]
12. Redox Mechanisms Influencing cGMP Signaling in Pulmonary Vascular Physiology and Pathophysiology.
Patel D; Lakhkar A; Wolin MS
Adv Exp Med Biol; 2017; 967():227-240. PubMed ID: 29047089
[TBL] [Abstract][Full Text] [Related]
13. Anti-fibrotic effects of soluble guanylate cyclase stimulators and activators: A review of the preclinical evidence.
Sandner P; Stasch JP
Respir Med; 2017 Jan; 122 Suppl 1():S1-S9. PubMed ID: 28341058
[TBL] [Abstract][Full Text] [Related]
14. cGMP Signaling in Cardiovascular Diseases: Linking Genotype and Phenotype.
Dang TA; Schunkert H; Kessler T
J Cardiovasc Pharmacol; 2020 Jun; 75(6):516-525. PubMed ID: 32487847
[TBL] [Abstract][Full Text] [Related]
15. Contemporary Approaches to Modulating the Nitric Oxide-cGMP Pathway in Cardiovascular Disease.
Kraehling JR; Sessa WC
Circ Res; 2017 Mar; 120(7):1174-1182. PubMed ID: 28360348
[TBL] [Abstract][Full Text] [Related]
16. [Nitric Oxide Signaling Pathway and Vascular Activity].
Gao YS
Sheng Li Ke Xue Jin Zhan; 2017 Feb; 48(1):58-62. PubMed ID: 29927223
[TBL] [Abstract][Full Text] [Related]
17. Impaired Pulmonary Arterial Vasoconstriction and Nitric Oxide-Mediated Relaxation Underlie Severe Pulmonary Hypertension in the Sugen-Hypoxia Rat Model.
Christou H; Hudalla H; Michael Z; Filatava EJ; Li J; Zhu M; Possomato-Vieira JS; Dias-Junior C; Kourembanas S; Khalil RA
J Pharmacol Exp Ther; 2018 Feb; 364(2):258-274. PubMed ID: 29212831
[TBL] [Abstract][Full Text] [Related]
18. A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of the Efficacy and Safety of the Oral Soluble Guanylate Cyclase Stimulator: The VICTORIA Trial.
Armstrong PW; Roessig L; Patel MJ; Anstrom KJ; Butler J; Voors AA; Lam CSP; Ponikowski P; Temple T; Pieske B; Ezekowitz J; Hernandez AF; Koglin J; O'Connor CM
JACC Heart Fail; 2018 Feb; 6(2):96-104. PubMed ID: 29032136
[TBL] [Abstract][Full Text] [Related]
19. Nitric Oxide-cGMP Signaling in Hypertension: Current and Future Options for Pharmacotherapy.
Ataei Ataabadi E; Golshiri K; Jüttner A; Krenning G; Danser AHJ; Roks AJM
Hypertension; 2020 Oct; 76(4):1055-1068. PubMed ID: 32829664
[TBL] [Abstract][Full Text] [Related]
20. Paracrine nitric oxide induces expression of cardiac sarcomeric proteins in adult progenitor cells through soluble guanylyl cyclase/cyclic-guanosine monophosphate and Wnt/β-catenin inhibition.
De Pauw A; Massion P; Sekkali B; Andre E; Dubroca C; Kmecova J; Bouzin C; Friart A; Sibille C; Gilon P; De Mulder D; Esfahani H; Strapart A; Martherus R; Payen V; Sonveaux P; Brouckaert P; Janssens S; Balligand JL
Cardiovasc Res; 2016 Oct; 112(1):478-90. PubMed ID: 27520736
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
